
Abbott, the global healthcare leader, today announced a strategic collaboration with Novo Nordisk India to commercialize Extensior®  for people living with type 2  diabetes. This partnership leverages Novo Nordisk’s scientific leadership in GLP-1s and Abbott’s strong distribution network to expand access in India to a high-quality, evidence-based diabetes therapy, beyond regions Novo Nordisk currently serves. Extensior® is a second brand of Ozempic®, the world’s most prescribed GLP-1 RA (receptor agonist) molecule.2


The collaboration brings together Novo Nordisk’s global GLP-1 leadership and Abbott’s strong India footprint, helping more people with type 2 diabetes benefit from modern, evidence-based diabetes therapies

Under the agreement, Abbott will commercialize Novo Nordisk’s semaglutide (Ozempic®) under the brand name Extensior®
Extensior® offers powerful HbA1c reduction, weight-loss benefits, and proven risk reduction of cardiovascular and kidney events in people with type 2 diabetes1.



Press Release | Abbott partners with Novo Nordisk India to launch Extensior®, broadening access to Semaglutide (Ozempic®) for advanced diabetes management